Author/Authors :
Erta?، Rag?p نويسنده Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Erta?, Rag?p , ?zyurt، Kemal نويسنده Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey ?zyurt, Kemal , Y?ld?z، Sinem نويسنده Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Y?ld?z, Sinem , Ula?، Y?lmaz نويسنده Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Ula?, Y?lmaz , Turasan، Abdullah نويسنده Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Turasan, Abdullah , Avc?، At?l نويسنده Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Avc?, At?l
Abstract :
Omalizumab is a recombinant humanized anti-Ig E monoclonal antibody used as the third line treatment of chronic spontaneous urticaria (CSU). We report four patients with severe antihistamine-resistant CSU, who developed angioedema, anaphylaxis and/or flare up of urticaria at different times following omalizumab therapy.
